Trial reportHormone research in paediatrics2026
Clinical Predictors of Good/Poor Response to Growth Hormone Treatment in Children with Idiopathic Short Stature.
Trial report in Hormone research in paediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
NordiNet® International Outcome Study-Observational Prospective Study on Patients Treated With Norditropin®
Registry of Patients Being Treated With Norditropin®, Recombinant Human Growth Hormone
Who cites it
7 citing papers in PubMed.
- Growth Hormone Treatment Response and Machine Learning-Based Prediction in Idiopathic GHD and ISS: Analysis of the Korean LG Growth Study.Clinical endocrinology · 2026Observational
- Healthy short stature.Archives of endocrinology and metabolism · 2026Review
- Interpretable Machine Learning for Predicting Suboptimal 12-Month Growth Response to Recombinant Human Growth Hormone in Children with Idiopathic Short Stature: A Dual-Center External Validation Study.Diagnostics (Basel, Switzerland) · 2026Article
- Association Between Socioeconomic Indicators and Growth Hormone Treatment Patterns for Idiopathic Short Stature in China: A Large-Scale Real-World Study.Advances in therapy · 2026Article
- Comparative Outcomes of GH Treatment in Pediatric Idiopathic Short Stature and GH Deficiency.Journal of the Endocrine Society · 2025Article
- Idiopathic Short Stature in the Genomic Era: Integrating Auxology, Endocrinology, and Emerging Genetic Insights.Children (Basel, Switzerland) · 2025Review
- Mental health conditions, physical functioning, and health-related quality of life in adults with a skeletal dysplasia: a cross-sectional multinational study.Orphanet journal of rare diseases · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionChildren with idiopathic short stature (ISS) are known to have varying responses to growth hormone (GH) treatment (GHT).
methodsWe conducted a post hoc analysis to identify clinical characteristics predictive of good and poor response during year 1 of GHT. Data from the NordiNet® IOS (NCT00960128) and the ANSWER Program (NCT01009905) were used. Patients were grouped according to their response to GHT; good, middle, and poor responders had a change in HSDS of >1.0, 0.4-1.0, and <0.4, respectively. Patients were also grouped according to their responsiveness to GH dose. Logistic regression modelling was performed to identify clinical characteristics predictive of response to GHT.
resultsThe response analysis set included 207 patients. Patients were 3-11 years old (males) or 3-10 years old (females) at the start of treatment and were prepubertal throughout year 1 of treatment. Age at the start of treatment (odds ratio [OR] 0.69, 95% confidence interval [CI] 0.5; 0.9, p = 0.0169) and distance from target HSDS (OR: 2.05, 95% CI: 1.1; 3.9, p = 0.0259) were found to be significant independent predictors of being in the good- versus poor-response groups. When patients were grouped according to their responsiveness to GH dose, a positive correlation between GH dose and change in HSDS was observed.
conclusionWe identified younger age and further distance from target HSDS as clinical predictors of response to GHT in a heterogenous population of children with ISS. Future studies, designed to identify the genetic determinants of response to GHT, could further facilitate individualisation of GHT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.